Cargando…
Opportunities for Ferroptosis in Cancer Therapy
A critical hallmark of cancer cells is their ability to evade programmed apoptotic cell death. Consequently, resistance to anti-cancer therapeutics is a hurdle often observed in the clinic. Ferroptosis, a non-apoptotic form of cell death distinguished by toxic lipid peroxidation and iron accumulatio...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235304/ https://www.ncbi.nlm.nih.gov/pubmed/34205617 http://dx.doi.org/10.3390/antiox10060986 |
_version_ | 1783714285457768448 |
---|---|
author | Fujihara, Kenji M. Zhang, Bonnie Z. Clemons, Nicholas J. |
author_facet | Fujihara, Kenji M. Zhang, Bonnie Z. Clemons, Nicholas J. |
author_sort | Fujihara, Kenji M. |
collection | PubMed |
description | A critical hallmark of cancer cells is their ability to evade programmed apoptotic cell death. Consequently, resistance to anti-cancer therapeutics is a hurdle often observed in the clinic. Ferroptosis, a non-apoptotic form of cell death distinguished by toxic lipid peroxidation and iron accumulation, has garnered substantial attention as an alternative therapeutic strategy to selectively destroy tumours. Although there is a plethora of research outlining the molecular mechanisms of ferroptosis, these findings are yet to be translated into clinical compounds inducing ferroptosis. In this perspective, we elaborate on how ferroptosis can be leveraged in the clinic. We discuss a therapeutic window for compounds inducing ferroptosis, the subset of tumour types that are most sensitive to ferroptosis, conventional therapeutics that induce ferroptosis, and potential strategies for lowering the threshold for ferroptosis. |
format | Online Article Text |
id | pubmed-8235304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82353042021-06-27 Opportunities for Ferroptosis in Cancer Therapy Fujihara, Kenji M. Zhang, Bonnie Z. Clemons, Nicholas J. Antioxidants (Basel) Perspective A critical hallmark of cancer cells is their ability to evade programmed apoptotic cell death. Consequently, resistance to anti-cancer therapeutics is a hurdle often observed in the clinic. Ferroptosis, a non-apoptotic form of cell death distinguished by toxic lipid peroxidation and iron accumulation, has garnered substantial attention as an alternative therapeutic strategy to selectively destroy tumours. Although there is a plethora of research outlining the molecular mechanisms of ferroptosis, these findings are yet to be translated into clinical compounds inducing ferroptosis. In this perspective, we elaborate on how ferroptosis can be leveraged in the clinic. We discuss a therapeutic window for compounds inducing ferroptosis, the subset of tumour types that are most sensitive to ferroptosis, conventional therapeutics that induce ferroptosis, and potential strategies for lowering the threshold for ferroptosis. MDPI 2021-06-21 /pmc/articles/PMC8235304/ /pubmed/34205617 http://dx.doi.org/10.3390/antiox10060986 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Perspective Fujihara, Kenji M. Zhang, Bonnie Z. Clemons, Nicholas J. Opportunities for Ferroptosis in Cancer Therapy |
title | Opportunities for Ferroptosis in Cancer Therapy |
title_full | Opportunities for Ferroptosis in Cancer Therapy |
title_fullStr | Opportunities for Ferroptosis in Cancer Therapy |
title_full_unstemmed | Opportunities for Ferroptosis in Cancer Therapy |
title_short | Opportunities for Ferroptosis in Cancer Therapy |
title_sort | opportunities for ferroptosis in cancer therapy |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235304/ https://www.ncbi.nlm.nih.gov/pubmed/34205617 http://dx.doi.org/10.3390/antiox10060986 |
work_keys_str_mv | AT fujiharakenjim opportunitiesforferroptosisincancertherapy AT zhangbonniez opportunitiesforferroptosisincancertherapy AT clemonsnicholasj opportunitiesforferroptosisincancertherapy |